273 related articles for article (PubMed ID: 25601488)
1. Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
Robesova B; Bajerova M; Hausnerova J; Skrickova J; Tomiskova M; Dvorakova D
Lung Cancer; 2015 Mar; 87(3):318-20. PubMed ID: 25601488
[TBL] [Abstract][Full Text] [Related]
2. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
Wang Y; Zhang J; Gao G; Li X; Zhao C; He Y; Su C; Zhang S; Chen X; Zhang J; Li W; Li B; Zhao J; Hou L; Wu C; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533
[TBL] [Abstract][Full Text] [Related]
3. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
Nilsson RJ; Karachaliou N; Berenguer J; Gimenez-Capitan A; Schellen P; Teixido C; Tannous J; Kuiper JL; Drees E; Grabowska M; van Keulen M; Heideman DA; Thunnissen E; Dingemans AM; Viteri S; Tannous BA; Drozdowskyj A; Rosell R; Smit EF; Wurdinger T
Oncotarget; 2016 Jan; 7(1):1066-75. PubMed ID: 26544515
[TBL] [Abstract][Full Text] [Related]
4. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
[TBL] [Abstract][Full Text] [Related]
5. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
6. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
[TBL] [Abstract][Full Text] [Related]
7. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
8. TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC.
Robesova B; Bajerova M; Liskova K; Skrickova J; Tomiskova M; Pospisilova S; Mayer J; Dvorakova D
Lung Cancer; 2014 Jul; 85(1):25-30. PubMed ID: 24792336
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
[TBL] [Abstract][Full Text] [Related]
10. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.
Sanders HR; Li HR; Bruey JM; Scheerle JA; Meloni-Ehrig AM; Kelly JC; Novick C; Albitar M
Cancer Genet; 2011 Jan; 204(1):45-52. PubMed ID: 21356191
[TBL] [Abstract][Full Text] [Related]
11. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
Wu YC; Chang IC; Wang CL; Chen TD; Chen YT; Liu HP; Chu Y; Chiu YT; Wu TH; Chou LH; Chen YR; Huang SF
PLoS One; 2013; 8(8):e70839. PubMed ID: 23951022
[TBL] [Abstract][Full Text] [Related]
12. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
de Figueiredo-Pontes LL; Wong DW; Tin VP; Chung LP; Yasuda H; Yamaguchi N; Nakayama S; Jänne PA; Wong MP; Kobayashi SS; Costa DB
J Thorac Oncol; 2014 Feb; 9(2):248-53. PubMed ID: 24419423
[TBL] [Abstract][Full Text] [Related]
14. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
[TBL] [Abstract][Full Text] [Related]
15. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer.
Sullivan HC; Fisher KE; Hoffa AL; Wang J; Saxe D; Siddiqui MT; Cohen C
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):239-44. PubMed ID: 25265433
[TBL] [Abstract][Full Text] [Related]
16. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
Takeuchi K; Choi YL; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Takada S; Yamashita Y; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y; Mano H
Clin Cancer Res; 2008 Oct; 14(20):6618-24. PubMed ID: 18927303
[TBL] [Abstract][Full Text] [Related]
17. New targets in advanced NSCLC: EML4-ALK.
Crystal AS; Shaw AT
Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
[TBL] [Abstract][Full Text] [Related]
18. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
[TBL] [Abstract][Full Text] [Related]
19. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
[TBL] [Abstract][Full Text] [Related]
20. A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.
Sakai K; Okamoto I; Takezawa K; Hirashima T; Kaneda H; Takeda M; Matsumoto K; Kimura H; Fujita Y; Nakagawa K; Arao T; Nishio K
J Thorac Oncol; 2012 May; 7(5):913-8. PubMed ID: 22722791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
